Overview
- Eli Lilly and Nimbus Therapeutics signed a multi-year research and licensing agreement to discover oral small-molecule therapies for obesity and metabolic diseases using Nimbus’ AI-driven platform.
- Lilly will provide $55 million in upfront and near-term payments, with up to $1.3 billion in potential milestones plus tiered royalties on future global sales.
- Nimbus will lead AI-enabled candidate discovery while Lilly contributes metabolic-disease expertise to develop an easy-to-take oral medicine.
- The companies have not disclosed the biological mechanism for the program, leaving open whether it involves GLP-1 pathways or a different drug class.
- The collaboration expands a 2022 Lilly–Nimbus relationship and follows Nimbus’ AI-originated deals such as a 2022 Takeda acquisition, as Novo Nordisk begins US sales of its semaglutide pill and Lilly’s orforglipron remains under FDA review.